Sygnature Discovery Acquires Peak ProteinsGemma Cann2022-06-30T11:28:07+01:00April 28th, 2022|BioCity Nottingham, News|
OMass Therapeutics Raises $100 million To Progress Drug Pipeline In Immunology And Rare DiseasesGemma Cann2024-11-28T14:55:20+00:00April 28th, 2022|BioCity Nottingham, News|
Milestone Anniversary ‘A Proud Landmark’ For V Formation’s DirectorsGemma Cann2025-08-11T11:52:26+01:00April 26th, 2022|BioCity Nottingham, News|
Invizius Awarded Second Biomedical Catalyst GrantGemma Cann2022-06-30T11:30:18+01:00April 26th, 2022|BioCity Glasgow, News|
Wilton Centre Attracts Companies For Green Industrial RevolutionGemma Cann2024-11-28T14:56:04+00:00April 25th, 2022|News, Wilton Centre|
Cellomatics Biosciences Wins Queen’s Award For EnterpriseGemma Cann2024-11-28T14:56:21+00:00April 21st, 2022|BioCity Nottingham, News|
Upperton Pharma Solutions Launches Nasal Delivery Development PlatformGemma Cann2022-06-30T11:32:23+01:00April 14th, 2022|News|
AbbVie Partners With Pioneer Group To Launch The Golden Ticket ProgrammeGemma Cann2024-11-28T14:08:06+00:00April 6th, 2022|Accelerator, Article, Investment, News|
Invizius Awarded Major Biomedical Catalyst GrantGemma Cann2022-06-30T11:33:29+01:00April 1st, 2022|BioCity Glasgow, News|
Absolute Antibody Licenses Novel Fc Silencing Technology From mAbsolveGemma Cann2024-11-28T14:56:42+00:00March 31st, 2022|News, Wilton Centre|
